Lifecore Biomedical
LFCR
88 hedge funds and large institutions have $235M invested in Lifecore Biomedical in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.1% less ownership
Funds ownership: 92.95% → 92.85% (-0.1%)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
5% less funds holding
Funds holding: 93 → 88 (-5)
23% less capital invested
Capital invested by funds: $306M → $235M (-$71.2M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPAM
Legion Partners Asset Management
Los Angeles,
California
|
+$12.5M |
| 2 |
RA
Royce & Associates
New York
|
+$2.74M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.62M |
| 4 |
Millennium Management
New York
|
+$986K |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$819K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Walthausen & Co
Malta,
New York
|
-$4.16M |
| 2 |
HCM
Harspring Capital Management
New York
|
-$2.56M |
| 3 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$2.44M |
| 4 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$2.26M |
| 5 |
AC
AltraVue Capital
Bellevue,
Washington
|
-$2.08M |
LFCR Hedge Fund Activity: Q1 2020 in Review
88 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2020, worth a combined $235M — down 23% from $306M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LFCR and 9 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 30 added.
The largest buyer was Legion Partners Asset Management, adding an estimated $12.5M. The largest seller was Walthausen & Co, cutting an estimated $4.16M.
- 88 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2020, down from 93 in Q4 2019.
- Funds reported $235M of Lifecore Biomedical stock for Q1 2020, down 23% quarter-over-quarter.
- 9 funds opened new Lifecore Biomedical positions in Q1 2020 and 14 closed out, a net change of -5 holders.
- The largest Lifecore Biomedical buyer in Q1 2020 was Legion Partners Asset Management, an estimated $12.5M added.
- The largest Lifecore Biomedical seller in Q1 2020 was Walthausen & Co, an estimated $4.16M sold.
Based on aggregated 13F filings for Q1 2020.